Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumoricidal, bactericidal, or viricidal macrophage activation

A macrophage and virus killing technology, applied in the direction of anti-tumor drugs, anti-viral agents, anti-bacterial drugs, etc., can solve the problem of unrelated development of tumor cell resistance.

Inactive Publication Date: 2012-07-18
查尔斯肯尼萨维奇 +1
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, destruction of tumor cells by macrophages is apparently not associated with the development of tumor cell resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumoricidal, bactericidal, or viricidal macrophage activation
  • Tumoricidal, bactericidal, or viricidal macrophage activation
  • Tumoricidal, bactericidal, or viricidal macrophage activation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019]

[0020]

[0021] US Patent Nos. 5,177,001 and 5,177,002 to Yamamoto, N. concerning the formation of GcMAF from Gc proteins in vivo in mammals are incorporated herein by reference. The present invention differs from other prior art by performing directly in vivo or ex vivo but exposing leukocytes to GcMAF in real time, or directly in vivo or ex vivo but producing endogenous GcMAF in real time from circulating Gc proteins.

[0022] Reference throughout the specification to "one embodiment" or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, appearances of the phrase "in one embodiment" and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.

[0023] The term "extracorporeal device" as used herein refers to any device used in a procedure in which blood is removed from the pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The activation of macrophages and methods for treating cancer, bacterial pathogens and viral pathogens are disclosed. In particular, Gc protein is converted to Gc-macrophage activating factor (GcMAF), in vivo or ex vivo. The GcMAF activates macrophages which can then target cancer cells, bacterial pathogens and / or viral pathogens. Alternatively, macrophages are activated by contacting them, in vivo or ex vivo, with GcMAF. Optionally, nagalase is inactivated in a patient receiving the present macrophage activating treatment by contacting the patient's blood with a Nagalase-binding ligand immobilized on an inert medium.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application 61 / 236,088, filed August 22, 2009, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to the activation of macrophages and methods of treating cancer, bacterial pathogens and viral pathogens. In particular, the vitamin D binding protein (Gc protein) is converted to Gc-macrophage activating factor (GcMAF) in vivo or in vitro. GcMAF activates macrophages, which then target cancer cells, bacterial pathogens, and / or viral pathogens. Alternatively, macrophages are activated by exposure to GcMAF, in vivo or in vitro. Alternatively, alpha-N-acetylgalactosaminidase (nagalase) is inactivated by contacting the patient's blood with an alpha-N-acetylgalactosaminidase-binding ligand immobilized on an inert medium. Background technique [0004] The uncontrolled growth of metastases that are resistant to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K47/48A61K47/30A61K47/38C07K14/47A61P35/00A61P31/00
CPCA61M1/34A61M1/3687A61K9/146A61K35/15A61K38/47A61K9/0092A61K38/1709A61K38/38A61K9/7007A61K9/143A61K9/0024A61K9/70A61K38/19A61M1/3679A61P31/00A61P31/04A61P31/12A61P35/00
Inventor 查尔斯·肯尼萨维奇罗伯特·希尔维兹
Owner 查尔斯肯尼萨维奇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com